However, future research should focus on identifying molecules that are specifically recognized by the cell surface receptors of metabolic organs, generating engineered EVs by fusion of these molecules with relevant EV surface molecules, and testing the tissue targeting ability of such engineered EVs in the context of metabolic diseases. Here, CD177 is linked to metabolic disease.